Soo Choon TAN, Suzana MUSTAFA, Norul Badriah HASSAN, Mahiran MUSTAFA, Ahmad Kashfi AB RAHMAN, Lee Lee LOW, Wan Nazirah WAN YUSUF

Exploring CYP2B6 activity by measuring the presence of nevirapine hydroxy metabolites in plasma

Background/aim: Nevirapine is a reverse-transcriptase inhibitor widely used in combination therapy to treat HIV infection. Nevirapine is extensively metabolized in the liver and CYP2B6 is mainly responsible for oxidation of 3-hydroxynevirapine (3-OH NVP). This study aims to explore CYP2B6 activity by measuring 2-hydroxynevirapine (2-OH NVP) and 3-OH NVP in plasma and to identify factors associated with nevirapine pharmacokinetic parameters. Materials and methods: A total of 112 patients were recruited and treated with nevirapine-based antiretroviral therapy. Plasma nevirapine and metabolite concentrations were assayed using high-performance liquid chromatography via liquid liquid extraction. Results: Thirty-nine (34.8%) of the patients had no 3-OH NVP detected in their plasma while 2-OH NVP was detected in all patients. Metabolite concentrations were low compared to nevirapine. Positive correlations were observed between nevirapine and its metabolites, 2-OH NVP (P < 0.01) and 3-OH NVP (P = 0.012). Nevirapine concentration was decreased when concomitantly administered with methadone. Univariate analysis showed that ALT level, AST level, and detection of 3-OH NVP were associated with nevirapine pharmacokinetic parameters. Conclusion: The variability of nevirapine pharmacokinetic parameters was caused by liver enzymes and the presence of 3-OH NVP metabolites. The presence of 3-OH NVP can probably be used to distinguished CYP2B6 activity and efficacy of nevirapine in patients with HIV infection.

PDF

___

1. MOH. Malaysian Statistics on Medicine 2009 & 2010. Petaling Jaya, Malaysia: Ministry of Health Malaysia; 2014.
2. Suleiman A. Global AIDS Response 2012. Kuala Lumpur, Malaysia: Ministry of Health; 2012.
3. MOH. Global AIDS Response Progress Report 2014. Petaling Jaya, Malaysia: Ministry of Health Malaysia; 2014.
4. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27: 1488-1495.
5. Lang T, Klein K, Fischer J, Nüssler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, Zanger UM. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11: 399-415.
6. Penzak SR, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan V, Alfaro RM, Kityo C, Formentini E, Masur H. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med 2007; 8: 86-91.
7. Chantarangsu S, Cressey TR, Mahasirimongkol S, Capparelli E, Tawon Y, Ngo-Giang-Huong N, Jourdain G, Lallemant M, Chantratita W. Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women. J Antimicrob Chemoth 2009; 64: 1265-1273.
8. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Décosterd L, Telenti A. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genom 2005; 15: 1-5.
9. Suzana M, Nazirah WYW, Badriah HN. Development and validation of HPLC-UV method for simultaneous determination of nevirapine, 2-OH nevirapine and 3-OH nevirapine in human plasma. International Journal of PharmTech Research 2014; 6: 49.
10. Fan-Havard P, Liu Z, Chou M, Ling Y, Barrail-Tran A, Haas DW, Taburet AM. Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state. Antimicrob Agents Ch 2013; 57: 2154-2160.
11. Cammett AM, MacGregor TR, Wruck JM, Felizarta F, Miailhes P, Mallolas J, Piliero PJ. Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis. Antimicrob Agents Ch 2009; 53: 4147-4152.
12. de Vries-Sluijs TEMS, Dieleman JP, Arts D, Huitema ADR, Beijnen JH, Schutten M, van der Ende ME. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 2003; 42: 599-605.
13. Kappelhoff BS, Crommentuyn KML, de Maat MMR, Mulder JW, Huitema ADR, Beijnen JH. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet 2004; 43: 845-853.
14. Arroyo E, Valenzuela B, Portilla J, Climent-Grana E, PérezRuixo JJ, Merino E. Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily. European J Clin Pharmacol 2007; 63: 669-675.
15. Kharasch ED, Regina KJ, Blood J, Friedel C. Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism. Anesthesiology 2015; 123: 1142-1153.
16. de Maat MMR, Huitema ADR, Mulder JW, Meenhorst PL, van Gorp ECM, Beijnen JH. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Brit J Clin Pharmaco 2002; 54: 378-385.
17. Brown KC, Hosseinipour MC, Hoskins JM, Thirumaran RK, Tien H, Weigel R, Tauzie J, Shumba I, Schuetz EG, McLeod HL et al. Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. Pharmacogenomics 2012; 13: 113-121.
18. Elsherbiny D, Cohen K, Jansson B, Smith P, McIlleron H, Simonsson USH. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. Eur J Clin Pharmacol 2009; 65: 71-80.
19. Moltó J, Valle M, Miranda C, Cedeño S, Miranda J, Santos JR, Negredo E, Vilaró J, Costa J, Clotet B. Once- or twice-daily dosing of nevirapine in HIV-infected adults: A population pharmacokinetics approach. J Antimicrob Chemoth 2008; 62: 784-792.
20. Wang J, Kou H, Fu Q, Han Y, Qiu Z, Zuo L, Li Y, Zhu Z, Ye M, Ma Q et al. Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection. PLoS One 2011; 6: e26739.
21. Martínez E, Blanco JL, Arnaiz JA, Pérez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, García-Viejo MA, Mallolas J et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15: 1261-1268.
22. Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 2007; 21: 2191-2199.
23. Musa N, Zulkafli MI, Talib N, Mohamad N, Fauzi H, Ismail R. Haplotypes frequencies of CYP2B6 in Malaysia. J Postgrad Med 2012; 58: 235-241.